Novavax, Inc. NVAX
7.96 USD 0.00 (+0.00%)
Regular-session close
7.90 -0.06 -0.75%
Pre-market · Nov 18, 9:22 AM ET
Day range unavailable
6.20 52-week range 13.39
- YTD
- +18.45%
- 1 year
- +21.16%
News
marketbeat.com Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial Novavax NASDAQ: NVAX is looking to expand partnerships around its vaccine technology while advancing a potential C. difficile vaccine and supporting partner Sanofi's development of a combination…
prnewswire.com Novavax to Participate in Jefferies London Healthcare Conference GAITHERSBURG, Md., Nov. 11, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conference: Jefferies London…benzinga.com B. Riley Securities Reiterates Buy on Novavax, Lowers Price Target to $16 B. Riley Securities analyst Mayank Mamtani reiterates Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $18 to $16.
benzinga.com Novavax Raises FY2026 Sales Guidance from $235.000M-$275.000M to $385.000M-$415.000M vs $380.285M Est Novavax (NASDAQ:NVAX) raises FY2026 sales outlook from $235.000 million-$275.000 million to $385.000 million-$415.000 million vs $380.285 million estimate.
benzinga.com Novavax Earns $125M Milestone Payment With Initiation Of Sanofi's Phase 3 Influence-COVID-19 Combination Vaccine Study Through Nuvaxovid Novavax (NASDAQ:NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's…
benzinga.com Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.
